Capricor Therapeutics Q2 net loss widens on higher expenses
CAPR•Key financial detail
- Q2 loss per share: $0.70
Capricor attributed higher costs to regulatory activities and commercial readiness for Deramiocel.
Cash position and outlook
Capricor said cash and cash equivalents at the end of the second quarter totaled $238 million, which it expects is sufficient to fund operations for at least the next 12 months.
The company said it will provide further financial guidance after there is greater regulatory clarity on Deramiocel and that it is advancing commercial readiness at a slower pace pending that clarity.
Q2 loss widens as expenses rise
Capricor Therapeutics said its second-quarter net loss widened as operating expenses increased during late-stage development.
The company reported no revenue for the quarter as its lead therapy, Deramiocel, remains under FDA review.
